Primary Aldosteronism in Western Norway

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-85
SponsorHaukeland University Hospital

About this trial

In this study the investigators aim to identify and include consecutively patients with primary aldosteronism (PA) diagnosed in the Western and Mid-parts of Norway, to describe the characteristics of these patients, to explore the cardiac effects of PA before and after specific treatment, and to identify long-term outcomes after treatment. One subgroup of the PA patients perform echocardiography to assess left ventricular systolic myocardial function before and after treatment. One subgroup of PA patients perform cardiac MRI to assess myocardial mass, myocardial fibrosis and myocardial function in rest and during stress, before and after treatment. For the cardiac MRI substudy, the PA patients are compared with a group of healthy controls, also included in the study.

From 2022 onwards, PA patients diagnosed or subtyped with adrenal vein sampling at Oslo University Hospital will additionally be included in the study, thereby providing a national registration of PA patients.

Eligibility criteria

Qualifiers

Verified diagnosis or strong suspicion of primary aldosteronism

Age 18-85

Disqualifiers

Active cancer disease at time of inclusion

Asthma/chronic obstructive pulmonary disease ,

Use of dipyridamole

Claustrophobia

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

300 Participants
are grouped into 3 trial groups

Sponsors and collaborators

Haukeland University Hospital

Lead sponsor

Oslo University Hospital

Collaborator

Helse Stavanger HF

Collaborator

Helse Fonna

Collaborator

University Hospital of North Norway

Collaborator

St. Olavs Hospital

Collaborator

Alesund Hospital

Collaborator